Jefferies raises target for Pfizer stock to USD 35.00

Published on 10/06/2026 at 09:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer's Phase 2 eczema study outperformed placebo at Week 16. Pfizer stock costs EUR 24.50 on October 6, 2026 after EUR 24.44, plus 0.25 percent.

Isometrisches 3D-Diagramm einer Pharma-Wertschöpfungskette, Symbolbild für Pfizer Inc — Isometrische 3D-Grafik der Pharma-Wertschöpfungskette zeigt Produktionsprozesse ähnlich Pfizer Inc., ISIN US7170811035, im Überblick, Illustration mit AI erstellt.

Jefferies raised its Pfizer price target from USD 34.00 to USD 35.00 and kept a Buy rating on October 2, 2026, giving Pfizer stock a fresh analyst catalyst. The move followed Pfizer's Phase 2 tilrekimig data in atopic dermatitis, which showed a clear treatment response against placebo.

Eczema data show a measurable gap

According to Business Wire on October 1, 2026, 62.50 percent of patients receiving 450 milligrams of tilrekimig every two weeks achieved EASI-75 at Week 16, compared with 19.90 percent on placebo. In the monthly 200 milligram group, the corresponding figures were 61.00 percent and 9.10 percent.

The result matters because tilrekimig is designed to block interleukin-4, interleukin-13 and thymic stromal lymphopoietin. Pfizer is advancing Phase 3 studies in atopic dermatitis and asthma, alongside a Phase 2b/3 study in chronic obstructive pulmonary disease, according to the October 1, 2026 release.

Guidance and earnings set the test

Pfizer's second-quarter 2026 revenue was USD 15.03 billion, while adjusted diluted earnings per share were USD 0.77 and reported diluted earnings per share were minus USD 0.04. Yahoo Finance reports that management lifted full-year 2026 revenue guidance to USD 60.50 billion to USD 62.50 billion from USD 59.50 billion to USD 60.50 billion.

The guidance midpoint therefore increased by USD 1.50 billion, or 2.48 percent, from the earlier USD 60.00 billion midpoint. Adjusted diluted earnings per share guidance remained USD 2.80 to USD 3.00, leaving the November report as the next major test of Pfizer's recovery strategy.

Target remains above the market price

finanzen.net says Jefferies analyst Akash Tewari raised the target from USD 34.00 to USD 35.00 while retaining Buy on October 2, 2026. Pfizer's primary listing is on the NYSE, where the stock was last quoted at USD 27.41 on October 5, 2026, against a USD 23.62 to USD 29.21 52-week range.

Pfizer's next scheduled report is November 3, 2026, when the company plans to publish its third-quarter 2026 performance report, according to Pfizer. That date places upcoming financial results alongside the pipeline evidence now supporting the higher analyst target.

Pfizer stock holds near EUR 24.50

Pfizer stock was trading at EUR 24.50 at Lang & Schwarz on October 6, 2026 at 9:23 a.m. CEST, plus 0.25 percent versus the prior close of EUR 24.44. The company had a market capitalization of USD 156.2 billion as of October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.